AstraZeneca announced forecast-beating revenue on Tuesday. AstraZeneca's chief executive on Tuesday teased the prospect of a weight-loss drug in development that the company moved into late-stage ...
LONDON — The head of drug maker AstraZeneca will retire next month, the company said. The Anglo-Swedish drug manufacturer announced the planned retirement of CEO and board member David Brennan, ...
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 ...
Another phase 3 trial, Chestnut, evaluated children who switched from Strensiq to efzimfotase alfa. The study showed ...
AstraZeneca’s chief executive on Tuesday teased the prospect of a weight-loss drug in development that the company moved into late-stage trials. The company said it’s starting a Phase III program on ...
− Year-on-year comparison reflects the sales-based milestones recognised in Q4 2024 + Reported EPS benefitted from reduction in R&D impairments For monetary values the unit of change is percent. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results